COVID-19 IMPACT SURVEY MAY 2020
Amid the COVID-19 crisis and the looming economic recession, the Pharmerging market worldwide will grow by a projected US$843.5 Million, during the analysis period, driven by a revised compounded annual growth rate (CAGR) of 11.5%. Pharmaceutical, one of the segments analyzed and sized in this study, is forecast to grow at over 9.9% and reach a market size of US$960.5 Million by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Pharmaceutical market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.
As part of the new emerging geographic scenario, the United States is forecast to readjust to a 11.5% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$34.4 Million to the region's size over the next 7 to 8 years. In addition, over US$34.1 Million worth of projected demand in the region will come from Rest of European markets. In Japan, the Pharmaceutical segment will reach a market size of US$62.8 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Pharmerging market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 9.9% over the next couple of years and add approximately US$113 Million in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Pharmerging market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.
Competitors identified in this market include, among others, Abbott Laboratories; AbbVie, Inc.; Alexion Pharmaceuticals, Inc.; Allergan PLC; Amgen, Inc.; Aspen Pharmacare Holdings Ltd.; Astellas Pharma, Inc.; AstraZeneca PLC; Baxter International, Inc.; Bayer AG; Biogen, Inc.; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Celgene Corporation; CSL Behring; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; Eli Lilly and Company; Endo International PLC; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Grifols SA; H. Lundbeck A/S; Hospira, Inc.; Johnson & Johnson; Kyowa Hakko Kirin Co., Ltd.; Mallinckrodt Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Mylan Pharmaceutical Pvt. Ltd.; Novartis AG; Novo Nordisk A/S; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sanofi SA; Shire PLC; Stada Arzneimittel AG; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd.; UCB SA